Background To determine clinical-pathologic variables in patients with a new diagnosis of hepatocellular carcinoma (HCC) and underlying hepatitis B vs. C infection. Methods Patients presenting to ...

The American Gastroenterology Association (AGA) issued a new clinical guideline recommending antiviral drugs for patients at high risk for hepatitis B reactivation. (Gastroenterology) Researchers ...

Hepatitis B and C still survive in the dark, driven by a lack of information, unhygienic medical procedures, and poor access to early diagnosis. In India alone, where close to 40 million people ...

As Hepatitis B infection is a major risk factor for developing HCC, increasing vaccination coverage among the population is important. This is more crucial for high-risk populations such as healthcare ...

Hepatitis, particularly types B and C, has a profound impact on liver health, often leading to serious conditions like cirrhosis and liver cancer. These viral infections initiate an inflammatory ...

Liver cancer, predominantly hepatocellular carcinoma (HCC), remains one of the most aggressive and leading causes of ...

Tecentriq in combination with bevacizumab will help the 70 or so New Zealanders diagnosed with Hepatocellular Carcinoma (HCC) each year.

Further studies that carefully assess risk factors for HCC occurrence after HCV viral eradication are needed to optimize individualized surveillance approaches. Hepatitis C virus (HCV) infection ...

which often goes undetected and silently progresses to HCC. Both Hepatitis B and Hepatitis C, diseases that are endemic in Aotearoa, can progress to HCC5. “More than 94,000 New Zealanders are ...

Considerations relevant to the care of patients who are subject to a cirrhosis-independent pathway to HCC should lead to proposed changes in current widely-adopted practices of screening for HCC ...